Executives at C.R. Bard say the company is on track for an early 2015 approval for its Lutonix drug-eluting balloon for treating peripheral artery disease.
C.R. Bard (NYSE:BCR) is on track for an early 2015 U.S. approval of its Lutonix drug-eluting balloon, company executives said yesterday after reporting earnings growth that topped expectations.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1pjUjXd
Cap comentari:
Publica un comentari a l'entrada